Man Group’s Elevation Oncology ELEV Stock Holding History

Man Group’s Portfolio ELEV Stock Details ELEV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-121,232	Closed	-$622K	–	2084
2024 Q1	$622K	Buy	+121,232	New	+$393K	﹤0.01%	1713

Other funds holding ELEV

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Man Group's ELEV Position: Q2 2024 in Review

Man Group sold out of Elevation Oncology (ELEV) in Q2 2024, closing a stake of 121,232 shares — an estimated $622K sold.

Man Group first reported a position in ELEV in Q1 2024 and held it in 1 quarter. The position peaked at $622K in Q1 2024. 81 funds tracked by Wall St. Rank hold ELEV as of Q2 2024.

Man Group reported no remaining Elevation Oncology position as of Q2 2024 after selling out during the quarter.
Man Group sold 121,232 Elevation Oncology shares in Q2 2024, an estimated $622K.
Man Group first reported a position in Elevation Oncology in Q1 2024 and held it in 1 quarter.
Man Group's Elevation Oncology position peaked at $622K in Q1 2024.
81 funds tracked by Wall St. Rank held Elevation Oncology as of Q2 2024.

Based on Man Group's 13F filing for Q2 2024, filed 14 Aug 2024.